65,437 trials
Non-Small Cell Lung Cancer
Primary: Progression-free Survival (PFS) — 5.6 Months
Hepatitis C, Chronic · Hepatitis C Virus
Primary: Percentage of Participants Who Achieved Sustained Virological Response as Assessed at End of Study — 81.2 Percentage of Participants
Insomnia · Insomnia Disorder
Primary: Sleep Quality — 1.77; 2.18 0-4 scale of sleep quality
Coronary Artery Disease
Primary: Number of Participants Who Were Responders or Low-Responders of Antiplatelet Therapy as a Result of Whole Blood Aggregometry Testing (See Outcome Measure Description)…
Anesthesia, General · Neuromuscular Blockade
Primary: Time From Start of Administration of Sugammadex to Recovery of the T4/T1 Ratio to 0.9 — 2.3; 1.4 minutes
Pneumococcal Infections
Primary: Percentage of Participants With Pre-specified Local Reactions — 14.3; 12.6; 6.5; 1.1 Percentage of Participants
Crohn's Disease
Primary: Crohn's Disease Histologic Index of Severity (CDHIS) — 7; 8; 6; 8 scores on a scale
Polycystic Ovary Syndrome
Primary: Measure Number of Adolescent Girls With PCOS Who Can be Successfully Recruited Into a Randomized Clinical Trial That Includes Lifestyle Modification — 10; 11; 11; 10…
Acute Myelogenous Leukemia
Primary: Overall Survival - Overall and by Calculated Strata (CSR 7-April-11) — 6.6; 6.4; 5.1; 5.5 months — p=0.9951
Conjunctivitis · Keratitis · Blepharitis
Primary: Signs and Symptoms Composite Score - Change From Baseline to Day 15 - PP Population — -11.63; -12.41 Scores on a scale
Osteoarthritis of the Knee
Primary: Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Visual Analog Scale (VAS) Pain Subscore — 27.8; 22.6 scores on a scale…
Pain
Primary: Change in the Patient Demand for the Narcotic Analgesic, Morphine, Post Surgery — 57.0; 48.7 milligrams
Kidney Transplantation
Primary: Core Study: Number of Patients With Composite Efficacy Endpoint — 7; 7; 3; 5 Participants
Hypertension
Primary: Change From Baseline in Mean 24-hour Ambulatory Systolic Blood Pressure — -0.3; -11.9; -15.3 mmHg
Thromboembolism
Primary: Composite of Recurrent VTE or VTE Death at 36 Months — 26; 18; 1404; 1408 Participants — p=0.0137